• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Truist reiterated coverage on Concert Pharmaceuticals with a new price target

    2/2/21 11:37:54 AM ET
    $CNCE
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $CNCE alert in real time by email
    Truist reiterated coverage of Concert Pharmaceuticals with a rating of and set a new price target of $22.00 from $30.00 previously
    Get the next $CNCE alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $CNCE

    DatePrice TargetRatingAnalyst
    10/5/2021$13.00 → $9.00Buy
    Mizuho
    More analyst ratings

    $CNCE
    SEC Filings

    See more
    • SEC Form 15-12G filed by Concert Pharmaceuticals Inc.

      15-12G - CONCERT PHARMACEUTICALS, INC. (0001367920) (Filer)

      3/16/23 9:00:55 AM ET
      $CNCE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form EFFECT filed by Concert Pharmaceuticals Inc.

      EFFECT - CONCERT PHARMACEUTICALS, INC. (0001367920) (Filer)

      3/14/23 12:15:21 AM ET
      $CNCE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form EFFECT filed by Concert Pharmaceuticals Inc.

      EFFECT - CONCERT PHARMACEUTICALS, INC. (0001367920) (Filer)

      3/14/23 12:15:15 AM ET
      $CNCE
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CNCE
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4: Stuart Nancy sold $50,380 worth of shares (6,048 units at $8.33) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 262,596 units (withholding obligation)

      4 - CONCERT PHARMACEUTICALS, INC. (0001367920) (Issuer)

      2/16/23 8:51:22 AM ET
      $CNCE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4: Munsie Jeffrey A sold $31,375 worth of shares (3,762 units at $8.34) as part of a pre-agreed trading plan, decreasing direct ownership by 4% to 88,049 units to cover withholding tax

      4 - CONCERT PHARMACEUTICALS, INC. (0001367920) (Issuer)

      2/16/23 8:49:56 AM ET
      $CNCE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4: Cassella James V sold $31,375 worth of shares (3,762 units at $8.34) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 173,061 units to satisfy withholding obligation

      4 - CONCERT PHARMACEUTICALS, INC. (0001367920) (Issuer)

      2/16/23 8:48:59 AM ET
      $CNCE
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CNCE
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Mizuho reiterated coverage on Concert Pharmaceuticals with a new price target

      Mizuho reiterated coverage of Concert Pharmaceuticals with a rating of Buy and set a new price target of $9.00 from $13.00 previously

      10/5/21 7:29:28 AM ET
      $CNCE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Truist reiterated coverage on Concert Pharmaceuticals with a new price target

      Truist reiterated coverage of Concert Pharmaceuticals with a rating of and set a new price target of $22.00 from $30.00 previously

      2/2/21 11:37:54 AM ET
      $CNCE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Truist Securities reiterated coverage on Concert Pharmaceuticals with a new price target

      Truist Securities reiterated coverage of Concert Pharmaceuticals with a rating of Buy and set a new price target of $22.00 from $30.00 previously

      2/2/21 11:13:03 AM ET
      $CNCE
      Biotechnology: Pharmaceutical Preparations
      Health Care